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Introduction
Streptococcus pneumoniae (pneumococcus) is the principal
agent of community-acquired pneumonia which may be
accompanied by bacteremia. In addition, this microorganism
causes meningitis, otitis media, sinusitis, conjunctivitis, and
endocarditis. Nasopharyngeal carriage of pneumococci is
very common and newborns are colonized rapidly. Despite
advances in chemotherapy and, in particular, the use of 
β-lactam antibiotics, morbidity and mortality rates for
pneumococcal infections remain high worldwide. For example,
pneumococcal pneumonia causes over one million deaths
each year in children younger than 5 years [45] and, among
the elderly, the case fatality rate for bacteremia approaches
40 percent. Management of pneumococcal infections used to
be relatively straightforward, and penicillin was generally the
antibiotic of choice. However, the emergence of antibiotic
resistance among S. pneumoniae isolates has led to a change
in approach [23]. The development of resistance in vitro to
penicillin G of pneumococci following serial passages in the
presence of the antibiotic and the stepwise transfer of
resistance were reported soon after the introduction of
penicillin. Penicillin-resistant pneumococci were first isolated
in 1967 from individuals living in Australia and Papua-New
Guinea. In 1978, fully resistant and multiple-drug resistant
pneumococci were discovered in South Africa and, shortly
afterwards, in many other countries [3] including Spain [16]. 
The pathogenicity of S. pneumoniae has been attributed to
various factors such as the capsule, the autolytic LytA amidase
and its cell wall target, the pneumococcal surface protein A
(PspA), the pneumolysin (Pnl), and the IgA1 protease, among
others [1]. Nevertheless, the capsule has long been known to
be the major virulence factor of the pneumococcus. Griffith
first reported that unencapsulated pneumococcal variants were
virtually avirulent [21]. Moreover, a major reduction in virulence
(by a factor of 105) is associated with capsule loss, and addition
of a type-specific polysaccharide antiserum increases
susceptibility to phagocytosis. It is recognized that the virulence
of S. pneumoniae depends on the amount [32] and composition
of the capsular polysaccharide [25] as well as the genetic
background of the pneumococcal strain in which the capsule
is synthesized [24].
The main function of the capsule is to prevent phagocytosis
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Functional organization of the gene
cluster involved in the synthesis of
the pneumococcal capsule
Summary Streptococcus pneumoniae is a major human pathogen and its capsular
polysaccharide has been shown to be the main virulence factor. The molecular
organization of the genes governing the formation of this capsule was not studied
until the 1990s. The capsular clusters (cap) of eight of the 90 known pneumococcal
types have now been studied. The cap operon, located between the dexB and aliA
genes, is arranged as a central region comprising the genes coding for the specific-
type polysaccharide, flanked by open reading frames that are mostly common to all
of the serotypes. The biochemical functions of 24 genes required for capsular
polysaccharide biosynthesis have been elucidated but the precise role of the flanking
regions in capsular formation is unknown. The natural genetic transformation
characteristic of pneumococci, the arrangement of the cap locus and the abundance
of transposable elements at this locus favor the genetic variability of the capsule in
this microorganism. These well-documented observations together with the finding
that some genes located outside the cap cluster may also participate in capsule
formation increase the complexity of pneumococcal infection control.
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(for a review, see [13]). Studies carried out by Robert Austrian
and others led to the development of the 23-valent capsular
polysaccharide vaccine in 1983 [44]. Unfortunately,
polysaccharides are thymus-independent antigens and infants
do not produce significant amounts of anti-polysaccharide
antibodies. In addition, the pneumococcal vaccine is poorly
immunogenic in elderly people and immunocompromised
patients. Nevertheless, the use of the 23-valent pneumococcal
vaccine is recommended for: (i) persons aged 65 years or over;
(ii) immunocompetent persons older than 2 years suffering
from a chronic illness or living in environments in which the
risk is high; (iii) asplenic patients older than 2 years; and (iv)
immunocompromised persons older than 2 years [2]. Due to
the limited efficacy of the current pneumococcal polysaccharide
vaccine, efforts are being made to develop a new generation of
polysaccharide-protein conjugate vaccines [10]. In fact, an
improved vaccine against S. pneumoniae is considered to be
among the top three vaccine priorities of industrialized countries.
Development of a conjugate vaccine against pneumococci
has, however, several major limitations. First, the conjugate
vaccine must contain as many of the polysaccharide types
as possible, but at least 90 different capsular polysaccharides
have been described in S. pneumoniae. This contrasts with
Haemophilus influenzae, for which virtually only one
serotype (1b) is clinically relevant. Second, the number of
different polysaccharides that can be conjugated to the protein
is limited by the amount of protein required to elicit
immunity. Third, as pneumococcal types differ in various
parts of the world, a series of alternative formulations should
be envisaged. An additional factor that should be taken into
account is that the pneumococcal types most frequently
causing disease in children (6A, 14, 19F, 23F) are different
from those isolated from adults, in whom types 1 and 3
predominate [42].
A possible alternative to anticapsular pneumococcal
vaccines, is the use of drugs capable of inhibiting the synthesis
of the polysaccharide. A rational approach to this aim requires
an in-depth knowledge of the genes (and proteins) involved in
the biosynthetic process. F. Griffith first described trans-
formation of the pneumococcal types in 1928 [21] when he
inoculated mice subcutaneously with a mixture of live
unencapsulated pneumococci and a vaccine of heat-killed
encapsulated pneumococci. The mice developed an infection
due to encapsulated pneumococci of the same type as the strain
from which the vaccine had been prepared. Sixteen years later,
Avery and co-workers showed that DNA was responsible for
inducing capsular transformation [9]. It was subsequently shown
that capsular genes are closely linked in the S. pneumoniae
chromosome and can be transferred together during
transformation. Inter-type transformation (transformation from
one capsular type to another) should, at least in principle, involve
the exchange of large pieces of DNA containing the genes
responsible for the synthesis of the sugar components of the
corresponding capsular polysaccharide as well as the
transferases involved in the polymerization step (for a review,
see [33]). Another interesting finding of the classic studies is
that the capsule is synthesized from activated sugars, usually
in the form of UDP-derivatives [34].
Molecular organization of pneumococcal
capsular genes
The modern and powerful techniques of molecular biology
were not used on pneumococcal capsule genes until the 1990s
[20]. Type 3 was selected for molecular study for several
reasons: (i) this serotype is the most frequent cause of invasive
diseases in adults worldwide; (ii) type 3 polysaccharide is
chemically simple and composed of alternating units of
glucose (Glc) and glucuronic acid (GlcA) (Table 1); (iii) the
colonial morphology of S3– mutants is easily distinguishable
from that of encapsulated strains; and (iv) most of the classic
genetic studies were carried out with this serotype. In 1993,
we first succeeded in cloning a DNA fragment from a type
3 pneumococcus able to transform an unencapsulated (S3–)
spontaneous mutant (strain M24) such that it produced the
S3+ capsule [18]. The sequence of the cloned fragment and
surrounding regions showed that the unencapsulated M24
strain (as well as other spontaneous S3– mutants) harbored
a mutation in a gene, cap3A, putatively encoding a UDP-
glucose dehydrogenase (UDP-GlcDH) [6, 18]. This enzyme
is responsible for the synthesis of UDP-GlcA from UDP-
Glc, both sugar nucleotides being the precursors for type 3
capsule biosynthesis. Further studies provided new insight
into the organization of the type 3 capsular gene cluster [5,
14, 15] (Fig. 1). The main conclusions raised by these studies
were: (i) this cluster consists of three genes, namely cap3A,
cap3B, and cap3C, that appear to be type-specific because
they do not hybridize with DNAs prepared from any other
serotype; (ii) the cap3 cluster is located in the S. pneumoniae
chromosome between the genes dexB and aliA, which
putatively encode, a glycosidase and an oligopeptide
permease respectively, and are not required for capsular
synthesis; (iii) the cap3ABC genes form an operon that is
transcribed from a promoter located immediately upstream
from cap3A; and (iv) between dexB and cap3A there is a
region putatively coding for 
two open reading frames (ORF) (labeled as orf1 and orf2
in Fig. 1). In addition, two incomplete ORFs were also found
in this region. Nevertheless, none of these ORFs appear to
be involved in type 3 capsular polysaccharide biosynthesis
because they are not transcribed in vivo [5].
Independently, Paton and co-workers worked out the
organization of the genes involved in the biosynthesis of
capsular polysaccharides of three different types belonging
to serogroup 19, namely, 19F, 19A, and 19B (Table 1 and
Fig. 1). In particular, pneumococci belonging to type 19F
frequently cause pediatric infections (see above), and capsular
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polysaccharides of types 19F and 19A are included in the
23-valent anti-pneumococcal vaccine. As shown in Fig. 1,
the organization of the three capsular clusters as a whole
presents a series of conserved features similar to those
highlighted above for the cap3 operon. The genes responsible
for type 19F and 19A biosynthesis (and presumably, also
those for type 19B capsule formation) are located between
dexB and aliA (sequence accession number AF094575, and
references [22, 36–38]). However, the four ORFs (two
incomplete) located downstream from dexB, that are cryptic
in type 3, together with the so-called specific genes, appear
to form part of a single operon (in these cases, cps19f, cps19a,
or cps19b). The four ORFs of the putative cps19 operons
(genes A to D) are essentially identical (90–95% identical
nucleotides) in the various capsular clusters sequenced so
far, with the exception of one of the two clinical isolates of
type 23F reported (sequence accession number AF057294,
and reference [43]). Downstream from the fourth ORF of the
cluster is a variable number of genes that have been shown
to be more or less type-specific according to results obtained
by Southern blot hybridization and direct sequencing of the
DNA of various serotypes [29, 37]. A similar arrangement
of capsular genes has also been reported for types 1 [39], 14
[28], 23F [43], and 33F [31]. However, direct experimental
evidence for the presence of an active promoter located just
upstream from the first gene of the cap/cps operon has only
been provided for types 1 [39], 14 and 33F [31].
Biochemical function of cap genes
As illustrated in Fig. 2, biochemical evidence concerning the
precise role of most cap genes is still lacking and the functions
attributed to these genes have been suggested based solely on
sequence comparisons (Table 2). The only capsular cluster that
has been completely characterized is cap3. In addition to genetic
evidence [4, 15, 18], the cap3A gene has been cloned in
Escherichia coli, and the overproduced protein identified as
a UDP-GlcDH [6]. Cap3B is the type 3 polysaccharide synthase,
and it has been demonstrated that this is the only protein
required to synthesize high molecular weight type 3 capsular
polysaccharide in S. pneumoniae or E. coli strains, provided
that they synthesize both UDP-Glc and UDP-GlcA [7].
However, mutational analysis of the cap3 genes revealed that
only the cap3C gene was dispensable for capsule synthesis
in all conditions tested [5, 15]. In addition, cap3C complements
a galU mutation in E. coli and, therefore, codes for a UDP-Glc
pyrophosphorylase [5].
Experimental evidence concerning the role of the four genes
involved in the biosynthesis of the type 14 capsule has recently
been provided. The cps14E gene has been demonstrated to code
for a glucosyl-1-phosphate transferase [26] responsible for the
first step of subunit synthesis for the type 14 capsule, the addition
of glucose to a lipid carrier [27]. Experimental evidence suggesting
that this step may also be the first in the biosynthesis of most of
the capsular polysaccharides of S. pneumoniae containing glucose
has recently been provided [29]. It is likely that the genes cps19fE
and cps19aE, which are almost identical to cps14E, play the same
role in the biosynthesis of their respective capsular polysaccharides.
The cps14G, cps14I, and cps14J genes code for a β-1,4-
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Table 1 Repeating structures in nine Streptococcus pneumoniae capsular polysaccharides
Type Monomer
1 →3)-α-D-Sugp-(1→4)-α-D-GalpA-(1→3)-α-D-GalpA-(1→a
(+0.3 OAc)
3 →3)-β-D-GlcpA-(1→4)-β-D-Glcp-(1→
14 →6)-β-D-GlcpNAc-(1→3)-β-D-Galp-(1→4)-β-D-Glcp-(1→
4                                 
1
β-D-Galp
19F →2)-α-L-Rhap-(1-PO4–→4)-β-D-ManpNAc-(1→4)-α-D-Glcp-(1→
19Ab A]    →3)-α-L-Rhap-(1-PO4–→4)-β-D-ManpNAc-(1→4)-α-D-Glcp-(1→
B]    →2)-α-L-Rhap-(1-PO4–→4)-β-D-ManpNAc-(1→4)-α-D-Glcp-(1→
3                                                                    2 
α-L-Fucp-(1-PO4–-1)      β-D-GlcpNAc-(1→3)-β-D-Galp-(1-PO4–
19B →4)-β-D-ManpNAc-(1→4)-α-L-Rhap-(1-PO4–→4)-β-D-ManpNAc-(1→4)-α-D-Glcp-(1→
3
1
β-D-Ribp-(1→4)-α-L-Rhap
23F →4)-β-D-Glcp-(1→4)-β-D-Galp-(1→4)-β-L-Rhap-(1→
2     3
1     PO4– 2-Gly-ol
α-L-Rhap
33F →3)-β-D-Galp-(1→3)-α-D-Galp-(1→3)-β-D-Galf-(1→3)-β-D-Glcp-(1→5)-β-D-Galf-(1→
2                       2
1                       (OAc)0.4
α-D-Galp
aD-Sug = 2-Acetamido-4-amino-2,4,6,trideoxy-D-galactose.
bTwo different capsular polysaccharides have been described depending on the growth conditions [30].
galactosyltransferase, a β-1,3-N-acetylglucosaminyl transferase,
and a β-1,4-galactosyltransferase, respectively, implicated in the
second, third, and fourth steps of type 14 capsule biosynthesis
[27, 28].
The gene cps19fK (and its homolog cps19bK) is likely to be
a UDP-N-acetylglucosamine-2-epimerase involved in the
synthesis of UDP-N-acetylmannosamine [37], the precursor of
one of the sugar components of the serogroup 19 repeating unit
(Table 1). The genes cps19fLMNO and their homologs in other
capsular clusters (see Fig. 1 and 2) encode enzymes involved in
dTDP-rhamnose (dTDP-Rha) biosynthesis (Glc-1-P-thymidylyl
transferase; dTDP-4-dehydrorhamnose 3,5-epimerase; dTDP-
Glc 4,6-dehydratase; and dTDP-4-dehydrorhamnose reductase)
as deduced from the finding that they can substitute for Shigella
flexneri rfbBDAC [37]. 
Genetic complementation of cap3A mutants and
biochemical characterization of the gene expressed in E. coli
have shown that Cap1K is a UDP-GlcDH [39]. It should
be emphasized that cap1K is only 65% identical to cap3A,
which encodes the type 3-specific UDP-GlcDH, suggesting
that the two genes may have been introduced into 
S. pneumoniae from different sources because no more than
5% divergence has been found for other pneumococcal genes.
In fact, phylogenetic analysis has indicated that Cap1K is
equally distant from Cap3A and from other UDP-GlcDH
such as, for instance, Streptococcus pyogenes HasB, E. coli
KfiD, and S. flexneri Udg [40]. Very recently, we have
characterized Cap1J as a UDP-galacturonate 4-epimerase,
the first enzyme of this class to be characterized at the
molecular level [41]. This enzyme is involved in the
interconversion of UDP-GlcA and UDP-galacturonic acid
(UDP-GalA). It should be kept in mind that UDP-GalA is
the precursor of GalA, one of the components of the type 1
capsular polysaccharide (Table 1). However, four ORFs
virtually identical to cps19fLMNO have been found in all
type 1 S. pneumoniae clinical isolates tested (Fig. 1) despite
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Fig. 1 Genetic organization of the
Streptococcus pneumoniae DNA region
containing capsular genes of different types.
Thick and thin arrows indicate complete 
and interrupted ORFs, respectively. 
Regions with more than 90% identical
nucleotides between serotypes, are shown by
identical shading. Other capsular genes are
shown as white arrows. Dotted and gray
arrows indicate, respectively, flanking genes
not involved in capsular synthesis and
IS-like elements. The “inverted match-stick”
represents putative transcription terminators.
The location of functional 
(      ) and putative 
(      ) promoters is also shown
the fact that type 1 polysaccharide does not contain Rha
(Table 1) [39]. As none of these genes, orf1 through orf4,
(Fig. 1) are needed for capsular biosynthesis in type 1
pneumococci they may be a nonfunctional remnant of the
capsular gene cluster of the ancestor of type 1 strains. This
observation provides clues to the clonal origin of capsular
types in S. pneumoniae.
Other genes involved in capsule
biosynthesis
With the exception of cap3C, all of the type-specific capsular
genes reported above appear to be required for capsular
polysaccharide biosynthesis in S. pneumoniae. Nevertheless,
other genes located outside the capsular gene cluster may also
be involved in capsule formation. Watson and co-workers
claimed that a region of the pneumococcal chromosome located
downstream from lytA, the gene coding for the main autolytic
enzyme of S. pneumoniae, is essential for the formation of the
type 3 capsule [47]. However, a pneumococcal strain with a
long deletion encompassing the lytA gene and its surrounding
regions was easily transformed to give the type 3 capsule, which
demonstrated that lytA and the DNA region located downstream
from this gene are not involved in the encapsulation of 
S. pneumoniae [19].
As most pneumococcal capsules contain Glc and/or
galactose (Gal) or various derivatives, in addition to other
sugars [46], UDP-Glc must play a central role in the
biosynthesis of the capsule. In addition, UDP-Glc is required
for the interconversion of Gal and Glc via the Leloir pathway
[17]. As reported above, cap3C codes for a UDP-Glc
pyrophosphorylase that catalyzes the formation of UDP-Glc
from Glc-1-P and UTP. No gene putatively coding for a
similar enzyme has been found in any of the capsular gene
clusters thus far investigated (Fig. 1 and 2, and Table 2). All
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Fig. 2 Schematic representation of
pneumococcal capsular genes of known
biochemical function. Symbols are 
as in Fig. 1
these premises strongly suggest that another gene may also
encode a UDP-Glc pyrophosphorylase that may also be
common to all pneumococci. Such a gene, designated galU,
has recently been cloned, sequenced, and overexpressed in
E. coli [35]. Knockout galU mutants of type 1 and type 3
pneumococci are unable to synthesize a detectable capsule.
Presumably, a similar result would be obtained for other
capsule types. As eukaryotic UDP-Glc pyrophosphorylases
appear to be completely unrelated to their prokaryotic
counterparts, it is conceivable that GalU may be an
appropriate target in the search for new drugs to control
the pathogenicity of pneumococci and other bacteria.
Genetic variability in S. pneumoniae
capsular genes
The striking diversity in the capsular gene clusters of 
S. pneumoniae studied to date, in which high levels of
similarity between genes involved in specific functions is
exceptional, strongly suggests the existence of underlying
mechanisms of genetic exchange. As S. pneumoniae is
naturally transformable, capsule type changes may take place
as a consequence of transformation events involving
homologous recombination mediated by the conserved DNA
regions that flank the type-specific genes. This has been
shown to be true both in in vitro and in vivo conditions. It
has been reported that type 19B transformants are recovered
after transformation of a recipient type 19F strain with a 10.5-kb
PCR product containing the cps19b genes and the flanking
regions homologous to some of the cps19f genes (Fig. 1).
However, in the last few years, several researchers have
reported that some clinically relevant (multiresistant)
pneumococcal strains are essentially identical in overall
genotype but differ in capsule type. This finding has been
interpreted as evidence that the new strains are the products
of a capsular transformation event from one serotype to
another. Very recently, Coffey and co-workers studied in
detail eight type 19F variants that were otherwise identical
to the major Spanish multiresistant 23F clone and confirmed
that recombination at the cap locus had taken place on at
least four occasions [12].
Transposition-like events may have also contributed to
capsular diversity in S. pneumoniae. As shown in Fig. 1A,
all of the capsular gene clusters of S. pneumoniae are flanked,
on one or both sides, by insertion sequence (IS) elements.
This is particularly evident in the region downstream from
dexB, in which copies of IS1167 or IS1202 are frequently
found either in active or in inactive form. An additional copy
of the IS1167 element is also located immediately
downstream from the cap1 operon followed by four cryptic
ORFs that putatively code for enzymes involved in the
synthesis of dTDP-Rha (see above). This finding suggests
that the type 1 pneumococcal strains arose via a transposition
event that took place in an ancestor strain that had Rha in its
capsular polysaccharide [39]. Besides, the formation of binary
encapsulated pneumococcal strains, that is, pneumococci
possessing two different cap clusters and synthesizing two
capsules, depends upon the presence of a copy of IS1167 in
that this element provides the homology required for the
insertion of the extra gene cluster into the S. pneumoniae
chromosome [39]. A partial, incomplete copy of a IS1167-
like element is located downstream from cap3C [5, 11].
Yother and co-workers [48] noted that upstream from the
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Table 2 Putative functions attributed to type-specific capsular gene products of Streptococcus pneumoniae
Proposed functiona Gene product
Glycosyl transferases
GalA transferase Cap1E
Glucosyl transferase Cps19aE, Cps23fE, Cap33fE
Galactosyl transferase Cap23fH, Cap33fF, Cap33fG, Cap33fJ
N-acetyl-mannosamine transferase Cps19f/a/bF
Rhamnosyl transferase Cps19f/a/bH, Cps23fF, Cps23fI
Other Cap1G, Cap33fH
Acetyl transferases Cap1F, Cap33fO
Repeating unit transporter Cap1I, Cps14L, Cps19f/a/bJ, Cap23fJ, Cap33L
Polysaccharide polymerase Cps14H, Cps19f/a/bI, Cps23fG
Others
UDP-galactopyranose mutase Cap33fN
UDP-N-acetylglucosamine 2-epimerase Cps19fK
Glycero-phosphotransferase Cps23fK
Glycero-2-phosphate dehydrogenase Cps23fL
Nucleotidyl transferase Cps23fM
N-glyceraldehyde-2-phosphotransferase Cps23fN
Unknown Cap1H, Cps14F, Cps14K, Cps19f/a/bG, 
Cps19bP, Cps19bR, Cap33fI, Cap33fK, Cap33fM
aBased on sequence and/or structural similarities.
cap3A gene, there is a partial ORF similar to the IS-like 
H-rpt (Hinc) repeat elements of E. coli. This kind of sequence
is also associated with polysaccharide biosynthetic loci in
Gram-negative bacteria. 
Perspectives
As shown in Fig. 2 and Table 2, only 24 of the 74 type-specific
genes apparently required for capsular polysaccharide biosynthesis
in the eight cap clusters deciphered in S. pneumoniae so far, have
been biochemically characterized. Much work is required to define
clearly the role of the remaining gene products. In particular, the
proteins putatively involved in the transport of the repeating unit
and the polymerization of the polysaccharide were identified
purely on the basis of hydrophobicity plots because these proteins
have no significant amino acid similarities. Hence, the question
of how the growing polysaccharide chain is transported out of
the cell and polymerized remains unanswered. Based solely on
partial sequence similarities, a role for cap/cpsCD gene products
in chain length regulation and export, and a regulatory role in
capsule gene expression for Cap/CpsA have been repeatedly
proposed [22, 27, 43]. However, the only experimental evidence
of a relationship between these genes and capsule biosynthesis
comes from insertion-duplication mutagenesis experiments [22].
As polar effects on the genes located downstream from the
insertion cannot be ruled out, the real role of cap/cpsABCD in
pneumococcal capsular biosynthesis remains to be elucidated. In
addition, as reported above, it has been demonstrated that the
corresponding ORFs in type 3 isolates are cryptic genes that
are not translated [5] and, consequently, their involvement in type
3 capsule biosynthesis can be ruled out.
To date, the cap cluster of only 8 of 90 capsular types in 
S. pneumoniae has been studied. Much additional work is
required before we can answer the question as to whether all
of the genes involved in the biosynthesis of all pneumococcal
capsular polysaccharides are arranged as described here. In
particular, it should be kept in mind that sites for the insertion
of capsular loci different from the usual dexB-aliA do exist 
[8, 39]. Nevertheless, with the exception of Griffith [21], who
reported a pneumococcal strain that agglutinated specifically
with sera of two different types, natural isolates of 
S. pneumoniae with two capsules have not been described so
far. In addition, the possibility that Griffith’s observation was
caused by some kind of immunologic cross-reactivity between
the capsular polysaccharides of the two pneumococcal strains
cannot be ruled out. However, the possibility of isolating
genetically binary pneumococcal strains, that is, strains with
two capsular loci, one inactivated by mutation and the other
responsible for the formation of the capsule, cannot be
excluded. If this were the case, capsule shifting would be
possible in these isolates by back mutation or replacement of
the inactive gene cluster. The increasing availability of capsular
genes that can be used as probes in hybridization experiments
should be a great help in answering this intriguing question.
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